| ˷5 յ 5 Ʈ ˱ Ұϴ ڳԴϴ.
1. 7 Ȯ ϴ ص10 Ưʸ ڳؽ ڽ Ѵ. 11 25~26 俹 ߰ 2~3 Ϲ û ̴. ǥְ ѱ̴.
俹 324 ߰ 29.54 1 ߴ. Ȯ 𰡴 7̴. 10~12 ϴ 30% ص ġ. ְ ѱ ڹ Ϸκ 3 ֿ ȯû(Dzɼ) οŰ ߴ. ȯû Ⱓ ڰ 90% ǻ翡 ָ ִ Ǹ.
ڽ A ̻ Ͽ ( Ưʻ)μ 11 4 忹ɻ Ҵ. 迡 ڽ ̹ °. ռ 3 û ɻ縦 ߴ. ù Ư û 6⸸̴.
Ǵ ݾ 680̴. 2Ⱓ (ڱ ÷ Ư ϡ , 162), ߺ(392), üڱ(72) ̴. ڱݼҿ ڱ ȸϴ ݾ üῡ ڱ ȹ̴.
2. , CRISPR õ Ư㡤 ƽþ ÷
CRISPR-Cas9 õ Ư㸦 ÷ ̴. 1999 ȭк â߰ ZFN ڰ(1), TALEN ڰ(2) ߿ ̾ 2012 CRISPR/Cas9 ڰ(3) ߿ ϸ鼭 ߴ.
ٽɱ (CRISPR/Cas9) ÷ ִ ǥ DNA ãư ٴ ̵ RNA(ٻ) Cas9 ܹ DNA ڸ ȿ Cas9 ¦ ̷ ü ڰ ÷ ̴.
ư ÷ ̼ Ѿ ڱ о ġ Ĺ о ϰ ִ. ġ ߴܰ迡 ǰȭ ̼ ƿ ü ϸ鼭 ܰ Ͻ ް, ǰ Ŀ Ǹž κ οƼ ϰ ȴ.
1뿡 3뿡 ̸ ȭ ܰ躰 ڰ ȸ. CRISPR/Cas9 ڰ õƯ㸦 ڱ ġ, ڱ /Ĺ ε, ڱ ġ ӻ 1 ̻ ġ κ Lead candidate ̰ų Pre-clinical ܰ迡 ִ.
ȸ ܰ ռ CAR-T ġ ȣ CARTherics 2022 Ͽ ̱ ӻ 1 ȹ̴. In vivo Programs --(CMT) ġ 2021 IND-enabling ܰ Ͽ 2022 ȿ Ȯ ̴.
(ڷ : IR BOOK)
3. ֿ 9 õƯ ϡƯȭ ñ
CRISPR ڰ õƯ㸦 ϰ ִ ƽþ ֿ 9 (ѱ/̱//ȣ/߱/Ϻ/̰/ε/ȫ) õƯ㰡 ϵǾ ִ. ڼ (Ư ǥ) 235 ϰ 48 Ư, 2 ǿž, 50 ǥ ϵǾ, 135 Ư̴.
̷ ڱ ÷ Ư㸦 Ưȭ (̼ ) ַϰ ִ. Ưȭ ڱ CRISPR ڰ õ/ Ǹ ̾ ڱ Ȯ Բ Ȯ , Ư ұ Ȯ, Ư ο ִ.
CVC , Broad Institute ˽ɻ(Interference) ϰ ִ. CRISPR ڰ õƯ ټ ڱ ˽ɻ Senior Party ġ ˷ CVC's ε Junior party 忡 ռ ߸ ߴٴ ؾϴ δ ִ.
ȸ ǰ ִ ̱ Ư ˽ɻ簡 2023 Ϸ Ǹ ˽ɻ ̱ ټ ϵ ̶ ȴٰ ߴ. ̱ ˽ɻ ü CRISPR Ư Ǹ ̿ ߰ ű ü ȴٰ ٿ.
(ڷ : IR BOOK)
4. 2023 &
Ưʸ ڽ 忡 Ѵ. ڱ ÷ ǷϿ 9 SCI ǿȭ(FACT)κ A Ҵ.
ȸ 2013 7 ۷ι KeyGene, 2014 12 ۷ι þ Thermo Fisher Scientific, 2017 8 ۷ι ڱ Monsanto ü ߴ. ٸ ߰ Ư , η Ȯ ΰǺ ս ߴ.
ڴ " 17 ü Annual Fee, Milestone Payment Ͽ "̶ " ̱ ˽ɻ(Interference) ȸ CRISPR ڰ õƯ ߸ (CVC , Broad Institute) Ͽ License ̲ ϰ ִ" ߴ.
2022ʹ HO ι Ǹŷ ̶ ߴ. ȸ 2022 21, 2023 871, 2024 1402 2023 þ ̴. Ҿ 2022 ڰ ӵǴ 2023 ڷ Ƽ δ.
(ڷ : ڼ)
5. ִ ؽ 3 ȣ 14%
ִִ ڽ ؽ̴. ؽ ֽ 1118347( 14.24%) Ϸκ 3 ѱŹ ǹŹȴ. 迵ȣ ǥ̻ 4 Ư ֽ 112332( 1.43%) Ϸκ 1Ⱓ Ű ѵȴ.
ؽ 9 濵 2 ִ ֿ ǰ üϿ 3 ȸ ǰ ϱ ִ. ֽ 68144( 8.66%) Ϸκ 3Ⱓ ڹ ǹϱ ߴ.
ڱ ߽ ȸ оߺ ȭϱ 2020 6 Ѱϴ 迵ȣ ǥ̻縦 ϸ ̺ȭ ǥ̻ ǥü ȸ縦 ̴.
迵ȣ ǥ̻(CTO) â Ͽμ ִ. 20Ⱓ ž ̸Ӻ ġ Ű溴 ġ ټ ؿ . 2002~2019 еƼ ǥ̻ ߰ R&D Ѱ ð ִ.
濵 Ѱϴ ̺ȭ ǥ̻(CEO) ѱſ, ũ, 2018 3 շߴ. 10, ̿ 迡 21 ̿ ؿ 繫, ũ, 濵, 濵 ݿ ɷ ϰ ִ.
( 0)